Lucid Diagnostics Inc. — FY2021 Form 10-K Summary
Reporting period: Year ended December 31, 2021. The filing was signed April 5, 2022. Lucid is a commercial-stage diagnostics company focused on EsoGuard, a laboratory-developed DNA test, and EsoCheck, an FDA-cleared esophageal cell-collection device. The financial statements are audited and presented under U.S. GAAP.
Financial results and liquidity
Amounts below are in millions of dollars except per-share data.
| Metric | FY2021 | FY2020 |
|---|---|---|
| Revenue | $0.500 | $0 |
| Cost of revenue / gross profit (loss) | $0.585 / ($0.085) | $0 / $0 |
| Sales and marketing | $5.260 | $1.305 |
| General and administrative | $12.778 | $1.532 |
| Research and development | $9.296 | $5.443 |
| Operating loss | ($27.419) | ($8.280) |
| Interest expense | $0.659 | $0 |
| Net loss / loss per share | ($28.078) / ($1.51) | ($8.280) / ($0.59) |
| Operating cash flow | ($17.668) | ($5.629) |
| Cash at year-end | $53.656 | $0.111 |
- 2021 revenue arose from a monthly-fee commercialization agreement with laboratory partner ResearchDx (RDx), effective August 2021; it was not described as broad-based test-sales revenue. Cost of revenue exceeded revenue, producing a gross margin of approximately negative 17%.
- Operating expenses rose substantially, including $9.599 million of stock-based compensation. Management attributed the increases to commercial expansion, clinical development, regulatory and professional services, and public-company costs.
- 2021 investing cash flow was negative $0.862 million, primarily for equipment. Financing cash flow was positive $72.075 million, including $64.336 million net IPO proceeds and $7.739 million of PAVmed working-capital advances. Cash increased by $53.545 million.
- At year-end, total assets were $58.999 million, current assets $57.303 million, total liabilities $4.260 million, and stockholders’ equity $54.739 million. The $22.4 million PAVmed promissory note was converted into 15,803,200 Lucid shares in October 2021; no promissory-note balance remained on the year-end balance sheet. The company reported $1.657 million due to PAVmed, primarily for fees, expenses, and employee costs.
- Management said available cash and committed capital sources were expected to fund operations for at least one year from issuance of the financial statements. It also expected recurring operating losses and continued reliance on debt or equity financing. The filing does not provide quantified revenue or profitability guidance.
Business developments and changes from the prior period
- Lucid completed its IPO in October 2021, issuing 5.0 million shares at $14.00 per share for $70.0 million gross proceeds and approximately $64.4 million net proceeds. The company reported using approximately $10.7 million of net proceeds by year-end.
- Revenue began in 2021 under the RDx commercialization agreement; FY2020 had no revenue. Net loss increased to $28.1 million from $8.3 million, while operating cash use increased to $17.7 million from $5.6 million.
- Commercialization expanded beyond gastroenterologists toward primary-care referrals and direct-to-consumer telemedicine. Lucid opened pilot test centers in Arizona and reported expansion into Utah, Nevada, and Colorado; pandemic-related healthcare limitations easing supported increased testing activity, according to management.
- EsoCheck had FDA 510(k) clearance and European CE marking. EsoGuard was marketed in the U.S. as an LDT, with CE self-certification reported. The combined EsoGuard/EsoCheck system had FDA Breakthrough Device designation but had not received PMA approval.
- After year-end, Lucid acquired assets from RDx to operate its own CLIA-certified, CAP-accredited laboratory and began testing there in March 2022. The filing describes a purchase price of up to $6.2 million and a separate three-year RDx management-services agreement with payments totaling approximately $1.8 million.
Outlook, risks, and unusual items
- Regulatory and reimbursement: Medicare set a payment determination of $1,938.01 per EsoGuard test effective January 1, 2021, but a Medicare local coverage determination remained pending. Private-payor coverage and collections were uncertain; the filing notes some out-of-network payments received through RDx. LDT regulation remained uncertain, and Lucid could not jointly market EsoGuard with EsoCheck as a combined IVD without FDA approval.
- Clinical milestones: Two international PMA-supporting trials were enrolling. Management projected enrollment completion by late 2022 or early 2023 and PMA submission in early-to-mid 2023; the filing gives both timelines, so the target date is not consistent. Enrollment, FDA review, and expanded studies could take longer and require substantial capital.
- Operating and financing risks: Lucid had limited operating history, minimal revenue, recurring losses, and negative operating cash flow. It relied on PAVmed for management and other services and remained majority controlled by PAVmed. Manufacturing, laboratory capacity, product acceptance, reimbursement, competition, and COVID-19 impacts were identified risks.
- Subsequent financing and related-party plans: In March 2022 Lucid entered a Cantor committed equity facility for up to $50 million, subject to conditions and share limits; shares would be sold at 96% of the applicable trading-day VWAP. The company agreed to pay Cantor $1.0 million for the commitment. The filing also describes planned transfers of CapNostics assets from PAVmed for $2.1 million and an EsoCure license from PAVmed with royalties and development-cost obligations.
- Controls and contingencies: Management concluded disclosure controls were effective at December 31, 2021, but the filing did not include management’s assessment or auditor attestation of internal control over financial reporting, citing the transition period for newly public companies. No material pending legal proceeding was reported; ordinary-course claims and litigation risks remain.
Most important facts for investors to verify
- Whether the $0.5 million reported revenue reflects recurring testing demand, and the subsequent trend in tests performed, collections, and revenue per test.
- Progress and timing of MolDx Medicare coverage, private-payor coverage, and actual reimbursement and collection rates versus the $1,938.01 Medicare payment determination.
- Enrollment progress and results for ESOGUARD-BE-1 and ESOGUARD-BE-2, and the current FDA PMA submission schedule and expected study costs.
- Cash burn, committed funding availability, use and dilution from the Cantor facility, and the company’s updated runway after laboratory and commercial expansion.
- Laboratory operating capacity, costs, dependence on RDx services, and execution of the RDx asset acquisition and transition.
- The basis for PAVmed ownership percentages: the filing reports approximately 75.8% including certain unvested awards in one section and approximately 79.98% after the IPO in another context. Also verify related-party fees, asset transfers, royalties, and governance implications.